Physician profile
Mark E Sipe
NPI 1003265679
$3,544.51
in general payments reported to CMS, 2019-2025
11 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $465 · 2022: $723 · 2023: $1,415 · 2024: $749 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,232.87 |
| Education | $123.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,073.91 | 2021-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $868.79 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $628.74 | 2021-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $293.69 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $277.53 | 2021-2025 | Lybalvi, Aristada |
| Indivior INC. | $199.69 | 2022-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.01 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $64.55 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $17.74 | 2021 | |
| Vanda Pharmaceuticals INC. | $16.91 | 2024 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $14.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sipe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.